GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Cyclically Adjusted PB Ratio

Vertex Pharmaceuticals (BSP:VRTX34) Cyclically Adjusted PB Ratio : 15.76 (As of Jan. 18, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-01-18), Vertex Pharmaceuticals's current share price is R$649.50. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was R$41.22. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 15.76.

The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:VRTX34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 13.08   Med: 23.29   Max: 39.61
Current: 13.89

During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 39.61. The lowest was 13.08. And the median was 23.29.

BSP:VRTX34's Cyclically Adjusted PB Ratio is ranked worse than
93.11% of 595 companies
in the Biotechnology industry
Industry Median: 1.57 vs BSP:VRTX34: 13.89

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share data for the three months ended in Sep. 2024 was R$83.961. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$41.22 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.38 24.01 15.70 15.05 16.02

Vertex Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.51 16.02 15.21 16.21 15.31

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=649.50/41.22
=15.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=83.961/133.0289*133.0289
=83.961

Current CPI (Sep. 2024) = 133.0289.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201412 2.937 99.070 3.944
201503 3.148 99.621 4.204
201506 2.849 100.684 3.764
201509 3.663 100.392 4.854
201512 3.703 99.792 4.936
201603 3.578 100.470 4.737
201606 3.391 101.688 4.436
201609 3.350 101.861 4.375
201612 3.906 101.863 5.101
201703 4.712 102.862 6.094
201706 5.491 103.349 7.068
201709 5.551 104.136 7.091
201712 6.598 104.011 8.439
201803 7.723 105.290 9.758
201806 9.936 106.317 12.432
201809 11.678 106.507 14.586
201812 16.875 105.998 21.178
201903 17.691 107.251 21.943
201906 19.040 108.070 23.437
201909 21.030 108.329 25.825
201912 24.110 108.420 29.582
202003 30.466 108.902 37.216
202006 37.494 108.767 45.857
202009 42.203 109.815 51.124
202012 42.990 109.897 52.039
202103 48.878 111.754 58.183
202106 44.617 114.631 51.778
202109 49.094 115.734 56.430
202112 56.109 117.630 63.454
202203 53.094 121.301 58.227
202206 58.819 125.017 62.589
202209 66.553 125.227 70.700
202212 70.987 125.222 75.413
202303 72.980 127.348 76.236
202306 72.818 128.729 75.250
202309 79.076 129.860 81.006
202312 83.568 129.419 85.899
202403 89.391 131.776 90.241
202406 77.106 132.554 77.382
202409 83.961 133.029 83.961

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (BSP:VRTX34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines